Skip to main content
Pay Bill Portals

Organ Health Publications

Renasight | Prospera Kidney | Prospera Lung | Prospera Heart

Renasight

  1. Chebib, F; et al. Genetic Testing in the Management of Adult CKD. Journal of the American Society of Nephrology. 2025
  2. Ojo, et al. 2025 APOL1 Conference Report. Kidney International. 2025
  3. Stein Q, Herman K, Deyo J, et al. Dual diagnosis of autosomal dominant polycystic kidney disease and sickle cell disease in a teenage male. Pediatr Nephrol. (2023). 38(9):3189-3192. doi: 10.1007/s00467-023-05873-6
  4. Stein Q, Westemeyer M, Darwish T, et al. Genetic Counseling in Kidney Disease: A Perspective. Kidney Medicine (2023). 5(7):100668. doi: 10.1016/j.xkme.2023.100668.
  5. Shi V, Stein Q, Clark D, et al. Isolated benign persistent proteinuria with novel association of CUBN (cubilin) variants. 11(6):e7502. doi: 10.1002/ccr3.7502
  6. Dahl N, Bloom MS, Chebib FT, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults With Chronic Kidney Disease. J Am Soc Nephrol ():10.1681/ASN.0000000000000249.
  7. Bleyer AJ, Westemeyer M, Xie J, et al. Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel. Am J Nephrol. 2022. 53(4):297-306.
  8. Singh G, Gohh R, Clark D, et al. Vignette-Based Reflections to Inform Genetic Testing Policies in Living Kidney Donors. Genes. 2022;13(4).
  9. Cocorpus J, Hager MM, Benchimol C, et al. COL4A4 variant recently identified: lessons learned in variant interpretation-a case report. BMC Nephrol. 2022;23(1):253.
  10. Tantisattamo E, Reddy UG, Ichii H, et al. Is It Time to Utilize Genetic Testing for Living Kidney Donor Evaluation? Nephron 2021. doi: 10.1159/000520150
  11. Mrug M, Bloom MS, Seto C, et al. Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists. Kidney Medicine

    (2021) doi: https://doi.org/10.1016/j.xkme.2021.08.006.

  12. Chaperon JL, Wemmer NM, McKanna TA, et al. Preimplantation Genetic Testing for Kidney Disease-Related Genes: A Laboratory’s Experience. Am J Nephrol 2021. doi: 10.1159/000518253

Prospera Kidney

  1. Bunnapradist S, Leca N, Zaky Z. et al. Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study. AJT. 2025
  2. Viklicky, et al. Targeting CD38 in Subclinical Antibody-mediated Rejection in HLA-incompatible Kidney Transplantation: A Case Report. Transplantation Direct. 2025
  3. Bromberg, et al. Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant. Transplantation. 2024
  4. Halloran, et al. Distinct Molecular Processes Mediate Donor-derived Cell-free DNA Release From Kidney Transplants in Different Disease States. Transplantation. 2023
  5. Halloran PF, Reeve J, Madill-Thomsen KS, et al. The Trifecta study: comparing plasma donor-derived cell-free DNA levels with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol. 2022. 33(2):387-400.
  6. Ventura-Aguiar P, Ramirez-Bajo MJ, Rovira J, et al. Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney. Transplantation. 2022;106(8):1690-1697.
  7. Reusing Jr JO, Yoo J, Desai A, et al. Association between total cell free DNA and SARS-CoV-2 in Kidney Transplant Patients: A Preliminary Study. Transplantation Proceedings. 2022; 54(6):1446-1454.
  8. Halloran PF, Reeve J, Madill-Thomsen KS, et al. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation. Transplantation. 2022.
  9. Halloran PF, Reeve J, Madill-Thomsen KS, et al. Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study. Transplantation. 2022.
  10. Qazi Y, Patel A, Fajardo M, et al. Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management. Transplant Proc. 2021. 10:S0041-1345(21)00710-7. doi: 10.1016/j.transproceed.2021.09.027.
  11. Lum EL, Nieves-Borrero K, Homkrailas P, et al. Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature. Transplantation Reports. 2021;6(3).
  12. Bunnapradist S, Homkrailas P, Ahmed E, et al. Using Both the Fraction and Quantity of Donor-Derived Cell-Free DNA to Detect Kidney Allograft Rejection. J Am Soc Nephrol 2021:32 (10) 2439-2441; DOI: 10.1681/ASN.2021050645
  13. Bunnapradist S, Datta N, Schaenman J, et al. Extremely High Cell-free DNA Levels Observed in Renal Allograft Patient With SARS-CoV-2 Infection. Transplantation Direct. 2021;7(5)
  14. Peabody J, Billings P, Valdenor C, et al. Randomized clinical trial of a novel donor derived cfDNA test to detect rejection in CPV-simulated renal transplant patients. Int Urol Nephrol. 2020; 52(8):1593-1601.
  15. Altug Y, Demko ZP, Ryan A. The Author's reply to the "Performance of Donor-derived Cell-free DNA Assays in Kidney Transplant Patients". Letter to the Editors - Transplantation. 2020;104(5):e135-137
  16. Peabody J, Billings P, Valdenor C, et al. Variation in assessing renal allograft rejection: a national assessment of nephrology practice. International Journal of Nephrology. Vol. 2019; Article ID 5303284, 6 pages.
  17. Altuğ Y, Liang N, Ram R, et al. Analytical Validation of a Single-Nucleotide Polymorphism-Based Donor-Derived Cell-Free DNA Assay for Detecting Rejection in Kidney Transplant Patients. Transplantation. 2019;103(12):2657-2665.
  18. Sigdel TK, Acosta Archila F, Constantin T, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2019;8(1):19.

Prospera Lung

  1. Goyal, et al. Surveillance Donor-derived Cell-free DNA Allows for the Safe Reduction in Protocol Transbronchial Biopsies After Lung Transplantation. Transplantation Direct. 2026
  2. Arunachalam, Ambalavanan et al. Donor-derived Cell-free DNA is a Valuable Monitoring Tool after Single Lung Transplantation: Multi-center Analysis JHLT Open, Volume 0, Issue 0, 100155
  3. Girgis R, Lawson C, Bhorade S, et al. Real-World Clinical Experience Implementing Donor-Derived-Cell Free DNA for Detection of Acute Lung Allograft Dysfunction after Lung Transplantation. Mar Pulmonology and Respiratory Medicine (2023) 6:3. DOI:10.1027/margy.2023.0156.
  4. Rosenheck JP, Ross DJ, Botros, M, et al. Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant. Transplantation Direct. 2022;8(4).
  5. Rosenheck JP, Keller BC, Fehringer G, et al. Why Cell-Free DNA Can Be a “Game Changer” for Lung Allograft Monitoring for Rejection and Infection. Curr Pulmonol Rep. 2022.
  6. Levine DJ, Demko ZP, and Ross DJ. Variability in plasma donor-derived cell-free DNA levels with CLAD more than 5-years after Lung Transplantation: Pilot data. Transplantation Reports. 2022;7(3).

Prospera Heart

  1. Kim PJ, Olympios M, Sideris K, et al. A Two-Threshold Algorithm using Donor-derived Cell-free DNA Fraction and Quantity to Detect Acute Rejection After Heart Transplantation. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2025.04.021.
  2. Deshpande SR, Zangwill SD, Richmond ME, et al. Evaluating Threshold for donor fraction cell-free DNA using Clinically Available Assay for Rejection in Pediatric and Adult Heart Transplantation. Pediatric Transplantation. 2024; 28:e14708. doi :10.1111/petr.14708.
  3. Halloran PH, Reeve J, Mackova M, et al. Comparing Plasma Donor-derived Cell-free DNA to Gene Expression in Endomyocardial Biopsies in the Trifecta-Heart Study. Transplantation. (2024): DOI: 10.1097/TP.0000000000004986.
  4. Kim PJ, Olymbios M, Siu A, et al. A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation. J Heart Lung Transplant. 2022.